The only current option for chemoprevention of LCIS/LBC in the context of HDGC is treatment with selective oestrogen receptor modulators (SERMS) or aromatase inhibitors. This evidence concerns the gene CYP19A1 and CDH1-related diffuse gastric and lobular breast cancer syndrome.